Sarah Kazzaz, MD
Rheumatology · Humble, TXNPI 1598100703
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 88.0% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $22,503, more than ten times the $692 reported in 2019.
Across 347 payments — averaging $102.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$31K
- AbbVie$1K
- Johnson & Johnson$1K
- UCB, Inc.$391
- GSK$330
- AstraZeneca$208
- plus $988 from 25 others
Across 6 payments — averaging $2599.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$16K
What the payments were for
- Consulting fees$8,93925%
- Speaking & faculty fees$18,00051%
- Travel & lodging$2,2156%
- Food & beverage$6,17817%
- Education$1991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 133 | $31,270 |
| AbbVie | 84 | $1,320 |
| Johnson & Johnson(2 entities) | 39 | $1,024 |
| UCB, Inc. | 12 | $391 |
| GSK | 17 | $330 |
| AstraZeneca | 13 | $208 |
| Aurinia Pharma U.S., Inc. | 8 | $152 |
| Novartis | 7 | $126 |
| IBSA Pharma Inc. | 2 | $124 |
| Antares Pharma, Inc. | 3 | $54 |
| Sandoz | 3 | $51 |
| Pfizer | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Fresenius Kabi USA, LLC | 2 | $41 |
| Bristol Myers Squibb | 2 | $36 |
| Boston Scientific | 1 | $33 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Pharming Healthcare, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| ADMA Biomanufacturing LLC | 1 | $20 |
| Abbott | 1 | $19 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,531 in reported general payments places this provider in the 85th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 62 | $334,775 |
| Humira(Cf) PenAdalimumab | 13 | $84,233 |
| ActemraTocilizumab | 11 | $51,400 |
| Mycophenolate Mofetil | 26 | $10,593 |
| Hydroxychloroquine Sulfate | 189 | $8,925 |
| Cevimeline Hcl | 14 | $4,950 |
| MethotrexateMethotrexate Sodium | 114 | $2,834 |
| Leflunomide | 20 | $1,439 |
| Prednisone | 123 | $1,179 |
| Colchicine | 14 | $487 |
| Folic Acid | 39 | $445 |
| Leucovorin Calcium | 30 | $377 |
| Gabapentin | 36 | $296 |
| Celecoxib | 23 | $288 |
| Allopurinol | 13 | $245 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Humble
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.